| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, November 2007, p. 4205-4208, Vol. 51, No. 11
0066-4804/07/$08.00+0 doi:10.1128/AAC.00647-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030-3411
Received 16 May 2007/ Returned for modification 3 July 2007/ Accepted 27 July 2007
In defined, isogenic strains, at least three mutations, two of which must be in gyrA, were required to exceed the CLSI breakpoint for fluoroquinolone resistance. Strains with double mutations in both gyrA and parC had even higher MICs of fluoroquinolones than strains with totals of three mutations.
Published ahead of print on 6 August 2007.
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |